OxTalks is Changing
During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).
If you have any questions, please contact halo@digital.ox.ac.uk
Targeting Dilemma of Immune Oncology
In person only.
Bent Jakobsen is a pioneer of T-cell receptor therapy for cancer with over two decades of experience establishing and providing scientific direction to leading T-cell receptor companies such as Adaptimmune Therapeutics and Immunocore (both now listed on NASDAQ). In his academic career, Bent was Head of the Immune Receptor Group at the Oxford Institute of Molecular Medicine (1993 to 2000) and before this worked for the Danish Natural Research Council and at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. He is currently the Chief Executive Officer of Accession Therapeutic Ltd. and holds non-executive director positions in several Biotechnology companies.
Date:
3 November 2025, 12:00
Venue:
MRC Weatherall Institute of Molecular Medicine, Headington OX3 9DS
Venue Details:
Seminar Room
Speaker:
Bent Jakobsen, PhD, FMedSci (CEO, Accession Therapeutics Ltd)
Organising department:
MRC Weatherall Institute of Molecular Medicine
Organiser contact email address:
seminar.admin@imm.ox.ac.uk
Host:
Prof Simon Davis (MRC Weatherall Institute of Molecular Medicine, University of Oxford)
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Yasmine Saito
